Brief: Biostage reports Q1 loss per share $0.14
May 11 (Reuters) - Biostage Inc BSTG.O :
* Biostage reports 2017 first quarter financial results and
provides business update
* Q1 loss per share $0.14
* Biostage Inc - remains on track to file ind with fda for
esophageal implant program in Q3 2017
* Biostage Inc - believes it has sufficient cash on hand to
fund operations through Q3 of 2017
Source text for Eikon: ID:nPn8s1Rjla
Further company coverage: BSTG.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Harvard Apparatus Regenerative Technology
See all newsBrief: Harvard Apparatus Regenerative Technology Announces Strategic Collaboration With Children’S Hospital Capital Institute Of Pediatrics In Beijing, China To Advance Treatment For Esophageal Atresia
Brief: Biostage Activated Mayo Clinic As The First Site For Clinical Trial In Severe Esophageal Disease
Brief: Biostage Amends CEO Employment Agreement
Brief: Biostage Inc Files For Firm Commitment Public Offering Of 1.03 Million Units - SEC Filing
Brief: Biostage Announces Appointment Of New Chief Financial Officer